Who Paid My Doc
William Oneill
Cardiovascular Disease Naples, FL Medical Doctor
NPI 1881676435 CMS profile 1071647
399 9Th St N Ste 300, Naples, FL 34102
General payments
$637,265
Research payments
$13,116
Ownership & investment interest
$84,474
Research they led as principal investigator
$4,002,180
Through program year 2025, William Oneill of Naples, FL is reported in the CMS Open Payments database as having received $637,265 across 506 general payments and $13,116 in research payments paid to them. Separately, studies naming them as principal investigator received $4,002,180 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $84,474 across 1 holding.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 99th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
13 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $44,961 | 27 | |
| 2025 | Research | $2,481 | 2 | |
| 2024 | General | $153,944 | 90 | |
| 2024 | Research | $9,896 | 27 | |
| 2023 | General | $217,599 | 118 | |
| 2023 | Research | $305 | 2 | |
| 2022 | General | $61,523 | 56 | |
| 2022 | Research | $355 | 2 | |
| 2021 | General | $76,241 | 80 | |
| 2020 | General | $40,366 | 46 | |
| 2019 | General | $42,631 | 89 | |
| 2019 | Research | $80 | 1 | |
| 2021 | Ownership | $84,474 | 1 |
Beside peers
- William Oneill
- Cardiovascular Disease median
- Middle half of Cardiovascular Disease
- National median
In program year 2025, general payments to William Oneill were reported at $44,961. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.
Show as a table
| Year | William Oneill | Cardiovascular Disease median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $42,631 | $450 | $127–$1,392 | $163 |
| 2020 | $40,366 | $242 | $77–$751 | $114 |
| 2021 | $76,241 | $335 | $101–$1,037 | $132 |
| 2022 | $61,523 | $395 | $121–$1,211 | $149 |
| 2023 | $217,599 | $443 | $136–$1,283 | $160 |
| 2024 | $153,944 | $450 | $136–$1,323 | $164 |
| 2025 | $44,961 | $432 | $132–$1,252 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 16 drugsPart D claims
277
Drug cost
$61,706
Branded share of claims
43.7%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 14 | $18,762 | |
| Repatha Sureclick Evolocumab | Brand | 12 | $14,158 | |
| Repatha Syringe Evolocumab | Brand | 12 | $12,186 | |
| Repatha Pushtronex Evolocumab | Brand | 19 | $10,786 | |
| Ranolazine Er Ranolazine | Brand | 11 | $1,718 | |
| Clopidogrel Clopidogrel Bisulfate | Brand | 53 | $957 | |
| Bumetanide | Generic | 11 | $684 | |
| Ezetimibe | Generic | 24 | $569 | |
| Potassium Chloride | Generic | 17 | $537 | |
| Metoprolol Succinate | Generic | 19 | $351 |
The 10 drugs with the highest cost, of 16 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 5 billing codesPaid by Medicare
$1,979
Medicare patients
28
Services billed
57
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Ischemic heart disease | 75% | |
| Arthritis | 54% | |
| Atrial fibrillation | 43% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
540 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Cardiovascular Disease in Florida
Kevin Makati
Cardiovascular Disease · Lutz, FL
Hiram Bezerra
Cardiovascular Disease · Tampa, FL
Theodore Feldman
Cardiovascular Disease · Miami, FL
John Gerald Canto
Cardiovascular Disease · Lakeland, FL
Alan Miller
Cardiovascular Disease · Jacksonville, FL
Seth Baum
Cardiovascular Disease · Boca Raton, FL
Related records
Cardiovascular Disease in Florida
Practitioners in the same specialty and state, ranked by reported value.
All Cardiovascular Disease
Everyone recorded under this specialty, nationwide.
Doctors in Florida
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.